- Home
- HURA vs ANIX Comparison
HURA vs ANIX Comparison
Compare HURA & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | ANIX |
|---|---|---|
| Founded | 2009 | 1982 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 104.0M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | HURA | ANIX |
|---|---|---|
| Price | $1.99 | $2.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $8.67 |
| AVG Volume (30 Days) | ★ 800.3K | 88.4K |
| Earning Date | 05-14-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $2.33 |
| 52 Week High | $4.41 | $5.46 |
Technical Indicators
Market Signals| Indicator | HURA | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 63.26 | 40.49 |
| Support Level | $1.56 | N/A |
| Resistance Level | $2.20 | $3.10 |
| Average True Range (ATR) | 0.20 | 0.19 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 66.45 | 38.10 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.